rdf:type |
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0012920,
umls-concept:C0015133,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0146224,
umls-concept:C0201734,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0684249,
umls-concept:C1705294,
umls-concept:C1709518
|
pubmed:issue |
2
|
pubmed:dateCreated |
2001-3-27
|
pubmed:abstractText |
In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of patients with advanced non-small-cell lung cancer (NSCLC).
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0344-5704
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
141-8
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:11269740-Adult,
pubmed-meshheading:11269740-Aged,
pubmed-meshheading:11269740-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11269740-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:11269740-Enzyme Inhibitors,
pubmed-meshheading:11269740-Etoposide,
pubmed-meshheading:11269740-Female,
pubmed-meshheading:11269740-Humans,
pubmed-meshheading:11269740-Hypoxanthine Phosphoribosyltransferase,
pubmed-meshheading:11269740-Lung Neoplasms,
pubmed-meshheading:11269740-Male,
pubmed-meshheading:11269740-Middle Aged,
pubmed-meshheading:11269740-Mutation,
pubmed-meshheading:11269740-Topoisomerase I Inhibitors,
pubmed-meshheading:11269740-Topoisomerase II Inhibitors,
pubmed-meshheading:11269740-Topotecan
|
pubmed:year |
2001
|
pubmed:articleTitle |
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
|
pubmed:affiliation |
Division of Hematology/Oncology, Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106, USA. axd44@po.cwru.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|